国际妇产科学杂志Issue(5)：560-563,4.
卵巢癌早期诊断的血清肿瘤标记物研究进展
Research Progress in Serum Tumor Markers of Early Diagnosis of Ovarian Cancer
摘要
Abstract
Ovarian cancer is the most leading cause of death in gynecologic malignancies. Since lack of early detection strategies, the majority of the patients are diagnosed at advanced stage disease, of which the cure rate is only 20%-30%. It has been observed that the survival rate of patients at early stages is higher than those diagnosed with advanced disease. Therefore, to improve the quality of patients′life, it is important and effective to get the early diagnosis methods of ovarian cancer. At present, transvaginal ultrasound combining with detection of serum tumor markers is the main clinical screening strategy. In order to improve the accuracy of early detection and diagnosis of ovarian cancer, in addition to carbohydrate antigen 125 (CA125), which is widely used to diagnosis of ovarian carcinoma, monitor its development and evaluate the prognosis, human epididymis protein 4 (HE4), osteopontin (OPN), mesothelin (MSLN) and costimulatory molecules B7-H4 also begin to become supplementary means for diagnosis of ovarian carcinoma. Then, OPN and B7-H4 can be used as ideal target genes and purpose for diagnosis of ovarian cancer. Detection of soluble mesothelin-related protein (SMRP) and OPN in patients′urine is a noninvasive method of diagnosis of ovarian cancer. This paper reviews the serologic tumor markers associated with ovarian cancer that had been verified at present.关键词
卵巢肿瘤/肿瘤标记,生物学/CA-125抗原/附睾分泌蛋白质类/骨桥蛋白质Key words
Ovarian neoplasms/Tumor markers,biological/CA-125 antigen/Epididymal secretory proteins/Osteopontin引用本文复制引用
岳娟,刘菲,李艳红..卵巢癌早期诊断的血清肿瘤标记物研究进展[J].国际妇产科学杂志,2015,(5):560-563,4.基金项目
卫生部医药卫生技术发展研究中心课题 （）
